The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Fintel reports that on January 16, 2025, UBS downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Buy ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...

UBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect ...

Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

General Douglas MacArthur High School senior Melody Hong has been named one of 300 semifinalists in the 2025 Regeneron ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Chen was one of 49 Long Island high school seniors named semifinalists Wednesday in the Regeneron contest, the country’s most ...